HK Stock MarketDetailed Quotes

01501 INT MEDICAL

Watchlist

27.100
-0.200-0.73%

Not Open Dec 19 16:08 CST

4.77BMarket Cap24.66P/E (TTM)

INT MEDICAL Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

(FY)Dec 31, 2020

(Q6)Jun 30, 2020

(FY)Dec 31, 2019

Turnover

15.47%392.32M

28.50%752.84M

50.86%339.76M

26.08%585.88M

24.70%225.22M

29.64%464.68M

5.10%180.61M

25.12%358.43M

--171.84M

41.07%286.46M

Operating income

15.47%392.32M

28.50%752.84M

50.86%339.76M

26.08%585.88M

24.70%225.22M

29.64%464.68M

5.10%180.61M

25.12%358.43M

171.84M

41.07%286.46M

Cost of sales

-4.40%-145.55M

-24.22%-314.77M

-37.77%-139.41M

-34.12%-253.4M

-56.46%-101.19M

-52.35%-188.93M

-11.47%-64.68M

-10.71%-124.01M

---58.02M

-32.31%-112.02M

Operating expenses

-4.40%-145.55M

-24.22%-314.77M

-37.77%-139.41M

-34.12%-253.4M

-56.46%-101.19M

-52.35%-188.93M

-11.47%-64.68M

-10.71%-124.01M

-58.02M

-32.31%-112.02M

Gross profit

23.17%246.77M

31.76%438.07M

61.54%200.35M

20.58%332.49M

6.98%124.02M

17.63%275.75M

1.86%115.94M

34.38%234.42M

113.82M

47.34%174.44M

Selling expenses

-1.77%-33.61M

-19.51%-67.4M

-52.00%-33.02M

-87.85%-56.39M

-61.89%-21.72M

-39.79%-30.02M

-5.19%-13.42M

10.37%-21.48M

---12.76M

-36.13%-23.96M

Administrative expenses

-51.75%-55.22M

-54.65%-99.43M

-28.17%-36.39M

-31.07%-64.29M

-37.16%-28.39M

-36.38%-49.05M

-8.48%-20.7M

-5.24%-35.97M

---19.08M

-66.67%-34.18M

Research and development expenses

-9.54%-70.75M

-26.31%-125.85M

-70.30%-64.59M

-10.76%-99.63M

15.83%-37.93M

-39.26%-89.96M

-49.10%-45.06M

-109.96%-64.59M

---30.22M

-39.22%-30.76M

Impairment and provision

35.55%652K

56.00%-407K

175.51%481K

-63.14%-925K

-2,023.33%-637K

-1,388.64%-567K

-130.77%-30K

109.52%44K

---13K

-81.08%21K

-Other impairment is provision

35.55%652K

56.00%-407K

175.51%481K

-63.14%-925K

-2,023.33%-637K

-1,388.64%-567K

-130.77%-30K

109.52%44K

---13K

-81.08%21K

Special items of operating profit

5.03%23.94M

-2.09%33.33M

4.51%22.79M

-32.15%34.04M

-7.00%21.81M

102.70%50.17M

-5.50%23.45M

-12.14%24.75M

--24.82M

190.62%28.17M

Operating profit

24.72%111.78M

22.74%178.32M

56.82%89.62M

-7.06%145.29M

-5.03%57.15M

13.96%156.32M

-21.40%60.18M

20.61%137.18M

76.57M

67.26%113.74M

Financing cost

14.36%-1.03M

-290.46%-3.19M

-274.22%-1.21M

-29.23%-818K

-2.22%-322K

-588.04%-633K

-556.25%-315K

94.96%-92K

---48K

-19.52%-1.83M

Earning before tax

25.26%110.75M

21.22%175.13M

55.58%88.42M

-7.21%144.47M

-5.07%56.83M

13.57%155.69M

-21.77%59.86M

22.49%137.09M

76.52M

68.36%111.91M

Tax

-46.25%-11.57M

-105.92%-21.9M

-18.02%-7.91M

30.24%-10.64M

21.77%-6.7M

25.88%-15.25M

27.48%-8.57M

-33.75%-20.57M

---11.82M

-86.69%-15.38M

After-tax profit from continuing operations

23.19%99.18M

14.49%153.23M

60.61%80.51M

-4.71%133.83M

-2.28%50.13M

20.54%140.45M

-20.72%51.29M

20.70%116.52M

64.7M

65.77%96.54M

Earning after tax

23.19%99.18M

14.49%153.23M

60.61%80.51M

-4.71%133.83M

-2.28%50.13M

20.54%140.45M

-20.72%51.29M

20.70%116.52M

64.7M

65.77%96.54M

Minority profit

-45,433.33%-1.36M

-252.31%-3.23M

100.42%3K

184.29%2.12M

-203.92%-716K

48.00%-2.52M

125.59%689K

-57.10%-4.84M

---2.69M

-1,332.09%-3.08M

Profit attributable to shareholders

24.89%100.54M

18.79%156.46M

58.34%80.5M

-7.87%131.71M

0.47%50.84M

17.80%142.96M

-24.91%50.61M

21.82%121.35M

67.39M

70.42%99.61M

Basic earnings per share

20.83%0.58

16.46%0.92

54.84%0.48

-8.14%0.79

3.33%0.31

17.81%0.86

-26.83%0.3

-7.59%0.73

0.41

16.18%0.79

Diluted earnings per share

23.40%0.58

17.95%0.92

56.67%0.47

-9.30%0.78

0.00%0.3

17.81%0.86

-26.83%0.3

-7.59%0.73

0.41

16.18%0.79

Currency Unit

CNY

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

KPMG Huazhen Certified Public Accountants (Special General Partnership)

Lixin Certified Public Accountants (Special General Partnership)

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021	(FY)Dec 31, 2020	(Q6)Jun 30, 2020	(FY)Dec 31, 2019
Turnover	15.47%392.32M	28.50%752.84M	50.86%339.76M	26.08%585.88M	24.70%225.22M	29.64%464.68M	5.10%180.61M	25.12%358.43M	--171.84M	41.07%286.46M
Operating income	15.47%392.32M	28.50%752.84M	50.86%339.76M	26.08%585.88M	24.70%225.22M	29.64%464.68M	5.10%180.61M	25.12%358.43M	171.84M	41.07%286.46M
Cost of sales	-4.40%-145.55M	-24.22%-314.77M	-37.77%-139.41M	-34.12%-253.4M	-56.46%-101.19M	-52.35%-188.93M	-11.47%-64.68M	-10.71%-124.01M	---58.02M	-32.31%-112.02M
Operating expenses	-4.40%-145.55M	-24.22%-314.77M	-37.77%-139.41M	-34.12%-253.4M	-56.46%-101.19M	-52.35%-188.93M	-11.47%-64.68M	-10.71%-124.01M	-58.02M	-32.31%-112.02M
Gross profit	23.17%246.77M	31.76%438.07M	61.54%200.35M	20.58%332.49M	6.98%124.02M	17.63%275.75M	1.86%115.94M	34.38%234.42M	113.82M	47.34%174.44M
Selling expenses	-1.77%-33.61M	-19.51%-67.4M	-52.00%-33.02M	-87.85%-56.39M	-61.89%-21.72M	-39.79%-30.02M	-5.19%-13.42M	10.37%-21.48M	---12.76M	-36.13%-23.96M
Administrative expenses	-51.75%-55.22M	-54.65%-99.43M	-28.17%-36.39M	-31.07%-64.29M	-37.16%-28.39M	-36.38%-49.05M	-8.48%-20.7M	-5.24%-35.97M	---19.08M	-66.67%-34.18M
Research and development expenses	-9.54%-70.75M	-26.31%-125.85M	-70.30%-64.59M	-10.76%-99.63M	15.83%-37.93M	-39.26%-89.96M	-49.10%-45.06M	-109.96%-64.59M	---30.22M	-39.22%-30.76M
Impairment and provision	35.55%652K	56.00%-407K	175.51%481K	-63.14%-925K	-2,023.33%-637K	-1,388.64%-567K	-130.77%-30K	109.52%44K	---13K	-81.08%21K
-Other impairment is provision	35.55%652K	56.00%-407K	175.51%481K	-63.14%-925K	-2,023.33%-637K	-1,388.64%-567K	-130.77%-30K	109.52%44K	---13K	-81.08%21K
Special items of operating profit	5.03%23.94M	-2.09%33.33M	4.51%22.79M	-32.15%34.04M	-7.00%21.81M	102.70%50.17M	-5.50%23.45M	-12.14%24.75M	--24.82M	190.62%28.17M
Operating profit	24.72%111.78M	22.74%178.32M	56.82%89.62M	-7.06%145.29M	-5.03%57.15M	13.96%156.32M	-21.40%60.18M	20.61%137.18M	76.57M	67.26%113.74M
Financing cost	14.36%-1.03M	-290.46%-3.19M	-274.22%-1.21M	-29.23%-818K	-2.22%-322K	-588.04%-633K	-556.25%-315K	94.96%-92K	---48K	-19.52%-1.83M
Earning before tax	25.26%110.75M	21.22%175.13M	55.58%88.42M	-7.21%144.47M	-5.07%56.83M	13.57%155.69M	-21.77%59.86M	22.49%137.09M	76.52M	68.36%111.91M
Tax	-46.25%-11.57M	-105.92%-21.9M	-18.02%-7.91M	30.24%-10.64M	21.77%-6.7M	25.88%-15.25M	27.48%-8.57M	-33.75%-20.57M	---11.82M	-86.69%-15.38M
After-tax profit from continuing operations	23.19%99.18M	14.49%153.23M	60.61%80.51M	-4.71%133.83M	-2.28%50.13M	20.54%140.45M	-20.72%51.29M	20.70%116.52M	64.7M	65.77%96.54M
Earning after tax	23.19%99.18M	14.49%153.23M	60.61%80.51M	-4.71%133.83M	-2.28%50.13M	20.54%140.45M	-20.72%51.29M	20.70%116.52M	64.7M	65.77%96.54M
Minority profit	-45,433.33%-1.36M	-252.31%-3.23M	100.42%3K	184.29%2.12M	-203.92%-716K	48.00%-2.52M	125.59%689K	-57.10%-4.84M	---2.69M	-1,332.09%-3.08M
Profit attributable to shareholders	24.89%100.54M	18.79%156.46M	58.34%80.5M	-7.87%131.71M	0.47%50.84M	17.80%142.96M	-24.91%50.61M	21.82%121.35M	67.39M	70.42%99.61M
Basic earnings per share	20.83%0.58	16.46%0.92	54.84%0.48	-8.14%0.79	3.33%0.31	17.81%0.86	-26.83%0.3	-7.59%0.73	0.41	16.18%0.79
Diluted earnings per share	23.40%0.58	17.95%0.92	56.67%0.47	-9.30%0.78	0.00%0.3	17.81%0.86	-26.83%0.3	-7.59%0.73	0.41	16.18%0.79
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion
Auditor	--	KPMG Huazhen Certified Public Accountants (Special General Partnership)	--	Lixin Certified Public Accountants (Special General Partnership)	--	Lixin Certified Public Accountants (Special General Partnership)	--	Lixin Certified Public Accountants (Special General Partnership)	--	Lixin Certified Public Accountants (Special General Partnership)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Trending HK Stocks